Valion Bio, Inc. short interest in 2025
In 2025, Valion Bio, Inc.'s disclosed short interest ran from 4.87% of shares outstanding on 31 Mar 2025 to 1.73% on 15 Dec 2025, a change of -3.14 percentage points. The year's high was 14.09% on 15 Aug 2025 and its low 1.73% on 15 Dec 2025, averaging 5.77% across 18 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 1.68 days on 15 Sep 2025. Full history: Valion Bio, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 4.87% (31 Mar 2025)
- End of year
- 1.73% (15 Dec 2025)
- Change
- -3.14 pp
- High
- 14.09% (15 Aug 2025)
- Low
- 1.73% (15 Dec 2025)
- Average
- 5.77%
- Highest days to cover
- 1.68 (15 Sep 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 31 Mar 2025 | 4.87% | 1.00 | 10-K filed, results (8-K) |
| 15 Apr 2025 | 8.63% | 1.00 | |
| 30 Apr 2025 | 9.37% | 1.00 | |
| 15 May 2025 | 6.28% | 1.00 | 10-Q filed, results (8-K) |
| 30 May 2025 | 4.90% | 1.00 | |
| 13 Jun 2025 | 4.26% | 1.22 | |
| 30 Jun 2025 | 3.57% | 1.58 | |
| 15 Jul 2025 | 2.90% | 1.33 | |
| 31 Jul 2025 | 4.36% | 1.08 | |
| 15 Aug 2025 | 14.09% | 1.00 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 9.05% | 1.00 | |
| 15 Sep 2025 | 7.93% | 1.68 | |
| 30 Sep 2025 | 6.51% | 1.00 | |
| 15 Oct 2025 | 6.37% | 1.00 | |
| 31 Oct 2025 | 3.46% | 1.12 | |
| 14 Nov 2025 | 3.27% | 1.00 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 2.34% | 1.00 | |
| 15 Dec 2025 | 1.73% | 1.00 |
See also: Valion Bio, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.